EATG » Hepatitis

Hepatitis

Hepatitis C drugs re-energize global fight over patents

Lawsuits in India and Argentina seek to reduce drug costs by allowing generic versions of antiviral treatments. The liver disease hepatitis C is the new battleground for lawsuits intended to…

Glecaprevir/pibrentasvir for HCV can be safely administered with common antiretrovirals

AbbVie's investigational glecaprevir/pibrentasvir treatment for hepatitis C is not expected to interact with or require dose adjustment when taken with commonly used antiretroviral regimens, offering a new option for HIV/HCV…

Medicines Patent Pool: 2017 prioritization report targeting new HIV and hepatitis C medicines for in-licensing

Geneva, February 28, 2017 – The Medicines Patent Pool released its 2017 prioritization report today selecting five HIV and two hepatitis C compounds for potential licensing agreements. The annual medicines…

FDA: TECHNIVIE label updated

On February 27, 2017 the TECHNIVIE  (fixed-dose combination of ombitasvir, paritaprevir, and ritonavir) label was updated to expand the indication to patients with genotype 4 chronic hepatitis C virus infection…

Vitamin D decreases HCV cell replication, aids virologic response

Vitamin D decreased hepatitis C cell replication and appeared significantly associated with rapid virologic response in anti-viral therapy, according to study results published in Hepatology Research. “Liver has long been…

AbbVie receives CHMP positive opinion for hepatitis C regimen

AbbVie receives CHMP positive opinion for eight-week treatment option with VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) for patients with genotype 1b chronic hepatitis C - CHMP opinion brings AbbVie…

Hepatitis A outbreaks among men who have sex with men: three clusters reported across 13 countries

Between February 2016 and February 2017, three clusters involving 287 confirmed cases of hepatitis A (HAV) have been reported across 13 EU countries: Austria, Belgium, Denmark, Finland, France, Germany, Italy,…

Are people with HIV and HCV co-infection who are cured of hepatitis C with DAAs at increased risk for liver cancer?

People with HIV and hepatitis C virus (HCV) co-infection who are successfully treated for hepatitis C using interferon-free direct-acting antiviral (DAA) therapy do not appear to have an increased likelihood…

ACIP recommends single-dose revaccination for infants born to HBV-infected mothers

The Advisory Committee on Immunization Practices voted today (February 22) in favor of a single-dose alternative to 3-dose revaccination for infants born to hepatitis B surface antigen-positive mothers who failed…

Ukraine signs agreement with Gilead on hepatitis C drug

KYIV. Feb 23 – Ukraine has signed an amicable agreement with U.S. Gilead Sciences, Inc. biopharmaceutical company on the Sovaldi medicine used to treat chronic hepatitis C infection in adults,…